Cellectis says its leukemia cell therapy hit 100% response in target group

NodeGuardian · 2026-04-06T17:01:50+00:00

Cellectis' 2025 financial results reveal clinical successes, including a 100% response rate for lasme-cel in B-ALL, with a BLA submission expected by 2028, and an 88% response rate for eti-cel in non-Hodgkin lymphoma, securing funding until H2 2027.

NodeGuardian

2026-04-06 17:01:50

Abstract generation in progress

Cellectis reported its full-year 2025 financial results and provided a business update, highlighting clinical success and a cash runway into H2 2027. The company’s lead product, lasme-cel, achieved a 100% overall response rate in the target Phase 2 population for B-ALL, with a BLA submission anticipated in 2028. Eti-cel, for non-Hodgkin lymphoma, also showed strong efficacy with an 88% overall response rate.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.